Bacillus anthracis is one of a limited number of biological agents capable of causing death and disease in sufficient numbers to devastate an urban setting. In October 2001, reports of American patients with inhalational anthrax reacquainted the public with this ancient disease and introduced the harsh reality of a bioterrorist act. Cutaneous disease, gastrointestinal anthrax and inhalational disease are the known clinical manifestations of anthrax. Inhalational anthrax has an untreated mortality of nearly 100% and is the primary cause of death for an exposed and unprotected population. Vaccination affords a high degree of primary prevention and multiple effective antibiotics exist for both disease prevention and treatment. In this article, we will discuss the costs and effectiveness of prevention strategies, diagnosis, and therapy of bioterrorism related anthrax.
Research Article: Journal of Infectious Diseases & Preventive Medicine
Research Article: Journal of Infectious Diseases & Preventive Medicine
Research Article: Journal of Infectious Diseases & Preventive Medicine
Editorial: Journal of Infectious Diseases & Preventive Medicine
Review Article: Journal of Infectious Diseases & Preventive Medicine
Posters & Accepted Abstracts: Journal of Clinical and Experimental Ophthalmology
Posters-Accepted Abstracts: Clinical & Experimental Cardiology
Accepted Abstracts: Clinical & Experimental Cardiology
Posters-Accepted Abstracts: Journal of Clinical & Experimental Dermatology Research